List view / Grid view
30 January 2015 | By electroCore
Non-invasive vagus nerve stimulation (nVNS) ‘improves the safety and tolerability of VNS making it more accessible and facilitating further investigations across a wide range of uses when compared with surgically implanted VNS’ according to a review in the European Journal of Neurology...
29 January 2015 | By The Astellas Innovation Debate
Two thirds (66%) of the population would want to know whether they had a risk of developing a serious illness, such as cancer, if genetic testing were available for free on the NHS...
29 January 2015 | By AstraZeneca
AstraZeneca has announced 4 research collaborations aimed at harnessing CRISPR, a pioneering genome-editing technique, across its entire discovery platform...
28 January 2015 | By BMG LABTECH
Since its establishment in 1990, BMG LABTECH has become a world leader in microplate reading due to continuous development of innovative and unique technologies...
Sartorius, a leading international laboratory and pharmaceutical equipment supplier, successfully closed fiscal 2014 according to its preliminary figures, and even slightly exceeded its sales revenue and earnings targets. In addition, the Group is set to further sharpen its strategic profile based on the sale of its smallest division, Industrial Technologies,…
28 January 2015 | By Frost & Sullivan
Frost & Sullivan says existing competitors’ dominance of the niche market raises entry barriers...
28 January 2015 | By Roche
Pharmaceutical giant Roche delivers its 2014 year-end results...
28 January 2015 | By The Astellas Innovation Debate
British patients happy to have webcam consultations – especially the over 55s...
28 January 2015 | By GlobalData
The acromegaly and gigantism treatment market will expand at a modest Compound Annual Growth Rate (CAGR) of 3.74% from approximately $588 million in 2013 to $707 million by 2018, limited by a sparse pipeline, according to research and consulting firm GlobalData...
Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the fourth quarter and full year of 2014, which were highlighted by strong global sales for priority brands and important advances in the company’s immuno-oncology (I-O) portfolio.
28 January 2015 | By Andrew Lloyd & Associates
ProveDye is a new sterile solution of methylene blue designed to aid visualization in surgical procedures. With ProveDye, Provepharm extends the Proveblue® methylene blue compound product range...
27 January 2015 | By Frost & Sullivan
Country-specific EHR implementation strategies will expedite market development, says Frost & Sullivan...
27 January 2015 | By Actavis
Actavis plc and the owners of Auden Mckenzie Holdings Limited, a dynamic and fast growing company focused on the development, licensing and marketing of niche generic medicines and proprietary brands in the UK, announced that they have reached a definitive agreement, under which Actavis will acquire Auden Mckenzie for approximately…
27 January 2015 | By Lukats and Shapiro
Half of UK bosses tempted to snoop on employees health app data to catch them ‘pulling a sickie’...
27 January 2015 | By Health Consumer Powerhouse
In spite of financial crisis, European healthcare keeps improving – but the equity gap widens...
